ArticleEJNMMI research2021
Hematologic safety of
Article in EJNMMI research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 50 citations in OpenAlex.
- Evaluation of the safety and efficacy ofEuropean radiology experimental · 2026Trial
- Theranostics for prostate cancer: A Canadian multidisciplinary expert report.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2026Article
- 177 Lu-PSMA for prostate cancer: progress, challenges and future perspectives.Asian journal of andrology · 2026Review
- Efficacy, safety, and quality of life outcomes of [International urology and nephrology · 2026Review
- Tumor microenvironment-mediated hematologic toxicity ofWorld journal of urology · 2026Review
- Acute complications of nuclear medicine: an emergency medicine perspective.EJNMMI research · 2026Review
- Focusing on Prostate-Specific Membrane Antigen in Precision Diagnosis and Treatment of Prostate Cancer.Biomedicines · 2026Review
- Effect of bone marrow disease on hematologic toxicity and response to [European journal of nuclear medicine and molecular imaging · 2026Article
- Radiopharmaceutical: An Update and Comparison of Preclinical Investigation Result of Alpha and Beta Emitter Radioisotope.Drug design, development and therapy · 2026Review
- Review
- Bridging the Gap: PSMA Radioligand Therapy for Asian Men with Prostate Cancer.Nuclear medicine and molecular imaging · 2025Review
- Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetiumHaematologica · 2025Article
- Article
- Development of a CT-less SPECT Acquisition Protocol for Kidney Dosimetry inMolecular imaging and biology · 2025Article
- First real-world clinical experience with [European journal of nuclear medicine and molecular imaging · 2025Article
- Hematological toxicity of [EJNMMI radiopharmacy and chemistry · 2025Article
- Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects duringTheranostics · 2025Review
- Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Review
- Hematological and renal toxicity in mice after three cycles of high activity [Scientific reports · 2024Article
- Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence.European journal of nuclear medicine and molecular imaging · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyelosuppression is a potential dose-limiting factor in radioligand therapy (RLT). This study aims to investigate occurrence, severity and reversibility of hematotoxic adverse events in patients undergoing RLT with
methodsRLT was performed in 140 patients receiving a total of 497 cycles. A mean activity of 6.9 [Formula: see text] 1.3 GBq
resultsSignificant (grade ≥ 3) hematologic adverse events occurred in 13 (9.3%) patients, with anemia in 10 (7.1%), leukopenia in 5 (3.6%) and thrombocytopenia in 6 (4.3%). Hematotoxicity was reversible to grade ≤ 2 through a median follow-up of 8 (IQR 9) months in all but two patients who died from disease progression within less than 3 months after RLT. Myelosuppression was significantly more frequent in patients with pre-existing grade 2 cytopenia (OR: 3.50, 95%CI 1.08-11.32, p = 0.04) or high bone tumor burden (disseminated or diffuse based on PROMISE miTNM, OR: 5.08, 95%CI 1.08-23.86, p = 0.04). Previous taxane-based chemotherapy was associated with an increased incidence of significant hematotoxicity (OR: 4.62, 95%CI 1.23-17.28, p = 0.02), while treatment with
conclusionHematologic adverse events after RLT have an acceptable overall incidence and are frequently reversible. High bone tumor burden, previous taxane-based chemotherapy and pretreatment grade 2 cytopenia may be considered as risk factors for developing clinically relevant myelosuppression, whereas cumulative RLT activity and previous
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.